An open study of methotrimeprazine in the management of nausea and vomiting in patients with advanced cancer

Kennett, A., Hardy, J., Shah, S. and Hern, R.A. (2005) An open study of methotrimeprazine in the management of nausea and vomiting in patients with advanced cancer. Supportive Care in Cancer, 13 5: 715-721. doi:10.1007/s00520-004-0768-1


Author Kennett, A.
Hardy, J.
Shah, S.
Hern, R.A.
Title An open study of methotrimeprazine in the management of nausea and vomiting in patients with advanced cancer
Journal name Supportive Care in Cancer   Check publisher's open access policy
ISSN 0941-4355
1433-7339
Publication date 2005-09
Sub-type Article (original research)
DOI 10.1007/s00520-004-0768-1
Volume 13
Issue 5
Start page 715
End page 721
Total pages 7
Place of publication Heidelberg, Germany
Publisher Springer
Language eng
Subject 1112 Oncology and Carcinogenesis
Formatted abstract
Introduction:
Nausea and vomiting are distressing symptoms affecting between 20% and 70% of patients with advanced cancer. Methotrimeprazine is a phenothiazine antipsychotic used in palliative care for the management of terminal agitation and nausea/vomiting but there is only anecdotal evidence to support its use in palliative care.

Aim:
To establish whether nausea/vomiting in palliative care patients is improved by the administration of low-dose methotrimeprazine.

Methods:

Patients with advanced malignancy were entered at different treatment levels according to symptom severity. The dose was altered according to response (minimum dose 6.25 mg daily po, maximum 25 mg by 24-h subcutaneous infusion). Symptoms and side effects were recorded daily from 0 (baseline) to day 5 using a four-point scale. Any improvement in nausea/vomiting score was taken as a response.

Results:
Sixty-five patients were entered. The cause of nausea and vomiting was multifactorial in the majority of patients, 35/65 (54%). As expected in a study of patients with poor performance status, the attrition rate was high. Of 53 patients evaluable for response at day 2, 33 (62%) showed some improvement in nausea or vomiting. At day 5, improvement was seen in 20/34 (58%). There was no significant change in "side effects" from baseline with time.

Conclusion:
These results suggest that methotrimeprazine has antiemetic activity.
Keyword Methotrimeprazine
Palliative care
Nausea
Vomiting
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Non-UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: Excellence in Research Australia (ERA) - Collection
School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 13 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 18 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Thu, 14 Jan 2010, 09:51:46 EST by Elissa Saffery on behalf of Faculty Of Health Sciences